<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang S</submitter><funding>Natural Science Foundation of Shandong Province</funding><funding>National Natural Science Foundation of China</funding><pagination>699-717</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8905236</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27</volume><pubmed_abstract>As one of the most common post-transcriptional modifications of mRNAs and noncoding RNAs, N&lt;sup>6&lt;/sup>-methyladenosine (m&lt;sup>6&lt;/sup>A) modification regulates almost every aspect of RNA metabolism. Evidence indicates that dysregulation of m&lt;sup>6&lt;/sup>A modification and associated proteins contributes to glioblastoma (GBM) progression. However, the function of fat mass and obesity-associated protein (FTO), an m&lt;sup>6&lt;/sup>A demethylase, has not been systematically and comprehensively explored in GBM. Here, we found that decreased FTO expression in clinical specimens correlated with higher glioma grades and poorer clinical outcomes. Functionally, FTO inhibited growth and invasion in GBM cells &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. Mechanistically, FTO regulated the m&lt;sup>6&lt;/sup>A modification</pubmed_abstract><journal>Molecular therapy. Nucleic acids</journal><pubmed_title>SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner.</pubmed_title><pmcid>PMC8905236</pmcid><funding_grant_id>ZR2019BH057</funding_grant_id><funding_grant_id>ZR2020QH174</funding_grant_id><funding_grant_id>81902540</funding_grant_id><funding_grant_id>81702468</funding_grant_id><pubmed_authors>Xue F</pubmed_authors><pubmed_authors>Li G</pubmed_authors><pubmed_authors>Pan Z</pubmed_authors><pubmed_authors>Fan Y</pubmed_authors><pubmed_authors>Guo X</pubmed_authors><pubmed_authors>Deng L</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Ni S</pubmed_authors><pubmed_authors>Zhang S</pubmed_authors><pubmed_authors>Guo Q</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Qiu W</pubmed_authors><pubmed_authors>Zhao S</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Zhao R</pubmed_authors><pubmed_authors>Jin C</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Qi Y</pubmed_authors><pubmed_authors>Gao Z</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Xue H</pubmed_authors></additional><is_claimable>false</is_claimable><name>SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner.</name><description>As one of the most common post-transcriptional modifications of mRNAs and noncoding RNAs, N&lt;sup>6&lt;/sup>-methyladenosine (m&lt;sup>6&lt;/sup>A) modification regulates almost every aspect of RNA metabolism. Evidence indicates that dysregulation of m&lt;sup>6&lt;/sup>A modification and associated proteins contributes to glioblastoma (GBM) progression. However, the function of fat mass and obesity-associated protein (FTO), an m&lt;sup>6&lt;/sup>A demethylase, has not been systematically and comprehensively explored in GBM. Here, we found that decreased FTO expression in clinical specimens correlated with higher glioma grades and poorer clinical outcomes. Functionally, FTO inhibited growth and invasion in GBM cells &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. Mechanistically, FTO regulated the m&lt;sup>6&lt;/sup>A modification</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T23:17:08.808Z</modification><creation>2025-04-04T23:17:08.808Z</creation></dates><accession>S-EPMC8905236</accession><cross_references><pubmed>35317283</pubmed><doi>10.1016/j.omtn.2021.12.035</doi></cross_references></HashMap>